Sequential Cytokine Delivery for Macrophage Phenotype Conversion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current wound healing technologies fail to promote the natural sequence of macrophage behavior in chronic wounds, leading to inadequate healing due to stalled inflammation and excessive scarring, as they either inhibit inflammation or do not ensure proper cytokine release post-M2A macrophage behavior.
Innovation Solution
A method involving the sequential conversion of wound macrophages from M1 to M2A and then to M2C phenotypes using a delivery system that administers IL-4 and IL-10, with hydrogel microspheres having an inner core bound to IL-10 and an outer shell bound to IL-4, to promote tissue remodeling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If anti-inflammatory technologies are used to inhibit M1 macrophage behavior, then inflammation is reduced, but wound healing is inhibited because inflammation is required for healing
Solution Approach 1:
The hydrogel microsphere delivers cytokines in a predetermined sequence: IL-4 is released first to convert M1 macrophages to M2A phenotype, followed by IL-10 release to convert M2A to M2C phenotype. This preliminary sequencing of cytokine delivery ensures that anti-inflammatory action occurs only after the initial inflammatory phase has served its healing purpose, resolving the contradiction between reducing inflammation damage and maintaining necessary inflammatory healing processes
2Productivity
If technologies promote the release of macrophage-stimulating cytokines, then macrophage activation is enhanced, but the proper cytokines are not released after M2A macrophage behavior subsides
Solution Approach 1:
The hydrogel microsphere is pre-programmed with sequential cytokine release capabilities through its layered structure. IL-4 is positioned to release first, followed by IL-10 release after M2A macrophage behavior subsides. This preliminary arrangement of cytokines in the hydrogel matrix ensures correct temporal sequencing, preventing loss of timing information while maintaining high macrophage activation
Solution Approach 2:
The hydrogel microsphere acts as an intermediary carrier that mediates the sequential delivery of cytokines to macrophages. The hydrogel matrix controls the timing and sequence of cytokine release, ensuring that IL-4 is delivered first to activate M2A phenotype, then IL-10 is delivered to promote transition to M2C phenotype, thereby preserving the correct cytokine release timing information
3Object-affected harmful factors
If hydrogels release anti-inflammatory molecules to inhibit M1 macrophages, then inflammation is controlled, but the natural wound healing sequence is not promoted
Solution Approach 1:
The hydrogel microsphere is pre-configured with a sequential cytokine release profile that mirrors the natural wound healing sequence. IL-4 is released first to promote M2A macrophage phenotype (proliferation phase), then IL-10 is released to promote M2C macrophage phenotype (remodeling phase). This preliminary sequencing restores the natural wound healing sequence while maintaining inflammation control, making the system adaptable to different healing stages
Data Source
AI summary
One aspect of the invention provides a method of treating a chronic wound including administering to the wound at least one agent from a delivery system wherein the agent induces sequential conversion of a first population of wound macrophages in the wound to M2A macrophages and a second population of wound macrophages to M2C macrophages. The sequential conversion of the wound macrophages promotes tissue remodeling.